Physidia, a France-based European leader in home haemodialysis (HHD), has acquired Finland-based Nordic Medcom, its long-standing partner and distributor in the Nordic region. The transaction marks a significant milestone in Physidia’s international development as it focuses on expanding access to home haemodialysis therapy across Europe.
Founded in 2010, Physidia is present in 18 countries and supports more than 1,400 patients worldwide, either through distribution partners or direct operations. Over 1.3 million dialysis sessions have been performed using its S³ system.
Nordic Medcom, founded and led by Mats Grenner, has established a strong presence across Finland, Sweden, and Denmark. The company generates approximately €6m in annual revenue, supports around 85 patients in HHD, and relies on a team of about 15 professionals dedicated to nephrology care. Through multiple long-term hospital partnerships and service agreements, Nordic Medcom has become an essential stakeholder in dialysis in the region.
After several years of close collaboration, shared projects, and joint expansion of home dialysis programmes, the acquisition of Nordic Medcom represents an opportunity for both parties.
Over the past years, Physidia has structured its international expansion progressively – including the recent launch of Germany offices – selecting markets based on their potential to develop therapy access based on robust clinical standards. This acquisition reflects that strategy: strengthening presence where therapy adoption can be expanded in close collaboration with local healthcare systems.
“Nordic Medcom has built deep clinical relationships and a solid presence in the region,” said Julien Dolivet, CEO of Physidia. “Mats Grenner wanted to lean back his company to a solid partner, capable to support Nordic Medcom growth. It was quite obvious for me that Physidia had a role to play.”
Beyond distributing Physidia’s S³ system, Nordic Medcom has built a broader dialysis-related portfolio and strong clinical collaborations. This acquisition therefore represents not only geographic expansion, but also an opportunity to extend and structure Physidia’s therapeutic offering in the Nordic markets.
“This acquisition strengthens our capacity to support healthcare professionals locally while expanding patient access to home haemodialysis,” said Grenner.
Nordic Medcom will continue to operate under the leadership of Grenner.
Columna Capital acquired a majority stake in Physidia in 2023.
Press release: Physidia acquires Nordic Medcom
